What the FDA labels say about taking them together
Insulin glargine and pramlintide
Insulin glargine's FDA label of June 16, 2026 names pramlintide in its drug interactions section; pramlintide's label does not name insulin glargine itself but warns about its class (insulin analogs). The insulin glargine label: “… disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. …”
Check it at the source: the insulin glargine FDA label on DailyMed (effective June 16, 2026, Eli Lilly and Company); the pramlintide FDA label on DailyMed (effective December 18, 2019, AstraZeneca Pharmaceuticals LP).
What does the insulin glargine label say about pramlintide?
Insulin glargine label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose reductions and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs.
Insulin Glargine label (Biocon Biologics Inc., January 23, 2026), drug interactionsDrugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when Insulin Glargine-yfgn is coadministered with these drugs.
Source: FDA drug label (Insulin Glargine, BLA761201), Biocon Biologics Inc., effective January 23, 2026 (SPL set 3ac85ebb-5594-59c8-77fd-df254329d151), via openFDA
Source: FDA drug label (Toujeo, BLA206538), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set c9561d96-124d-48ca-982f-0aa1575bff36), via openFDA
Source: FDA drug label (BASAGLAR KwikPen), Eli Lilly and Company, effective June 16, 2026 (SPL set 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae), via openFDA; the full label on DailyMed
What does the pramlintide label say about insulin glargine?
Pramlintide's label does not name insulin glargine itself; it warns about its class (insulin analogs):
Pramlintide label, boxed warningSEVERE HYPOGLYCEMIA SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes.
Pramlintide label, boxed warningAppropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk.
Source: FDA drug label (SymlinPen), AstraZeneca Pharmaceuticals LP, effective December 18, 2019 (SPL set 4aea30ff-eb0d-45c1-b114-3127966328ff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin glargine | Pramlintide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.90 per mL 100 pen | n/a |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once